PAIN TRIGGERS
Strattera causes extreme anhedonia and emotional flattening despite benefits to executive function and RSD.
Single ADHD medications fail to address full range of symptoms.
SaaS· ADHD patientsPain 7.00/10WTP 6.0/10Market 7.0/10Validation 7.0Confidence 72%May 23, 2026
ComboCalm: ADHD Med Regimen Tracker for Balanced Symptom Coverage
Strattera improves executive function but causes anhedonia and emotional flattening, while stimulants address motivation but leave executive dysfunction unaddressed, making single-med or blind combo trials frustrating and incomplete.
ai-powereddata-managementfreelancershealthcaremental-healthproductivitysaaswellness
1
STAGE 01 · PROBLEM
Is the problem real?
CANONICAL PROBLEM
ADHD medications like Strattera provide benefits for executive function, routines, memory, and emotional regulation but cause anhedonia and emotional flattening, while stimulants cover motivation and focus but not executive dysfunction.
FREQUENCY
Limited repetition signal.
INTENSITY
Users explicitly describe existing tools as bloated/overkill and mention workaround behavior.
EVIDENCE
Second time trying Strattera
ADHD210
Second time trying Strattera
ADHD210
2
STAGE 02 · CUSTOMER
Who feels this pain?
TARGET USERS
ADHD patientsA D H D Medication Experimenters
ADHD patients who have tried multiple single medications and are actively testing low-dose combinations of non-stimulants like Strattera with stimulants to achieve full symptom relief.
Context
Identify an effective medication regimen or combination that comprehensively manages ADHD symptoms without severe side effects like anhedonia.
Trying low-dose Strattera combined with existing stimulant to counteract anhedonia.
Switching between and combining multiple ADHD medications after prior trials.
Current Workarounds
Manually journaling symptoms across different doses and combos in notes apps
Trial-and-error switching between meds based on self-reported effects
Consulting online forums for anecdotal combo advice
3
STAGE 03 · MARKET
Where's the gap?
EXISTING SOLUTION GAPS
Strattera alone leads to anhedonia despite executive function gains.
Stimulants like Mydayis do not help with routines, memory, or emotional regulation.
Low-dose Strattera + stimulant combo causes uncomfortably quiet mind and flattened emotions.
OPPORTUNITY & VALUE
Why Now
Repeated mentions of incomplete symptom coverage and anhedonia trade-offs when using Strattera or stimulants alone or in low-dose combos.
Value Proposition
Focused exclusively on multi-med ADHD regimens and side-effect balancing rather than general habit or focus tracking
Product Direction
A specialized symptom logging app that tracks daily executive function, motivation, emotional state, and side effects against specific med/dose combos with visual pattern analysis.
4
STAGE 04 · BUSINESS
How does it make money?
MONETIZATION
$12/moIndividual user tracking and insights
Model
SaaS subscription
WILLINGNESS TO PAY
Users already invest significant time and emotional energy in dangerous self-experimentation with combos; clear frustration with incomplete relief and anhedonia indicates they would pay for structured tracking that reduces trial-and-error chaos.
5
STAGE 05 · EXECUTION
How do you ship it?
MVP PLAN
“Find a balanced ADHD regimen without anhedonia in 6 weeks.”
A specialized symptom logging app that tracks daily executive function, motivation, emotional state, and side effects against specific med/dose combos with visual pattern analysis.
Core Features
Daily symptom logging tied to specific meds and dosages
Side effect severity tracker for anhedonia and emotional flattening
Combo history visualizations comparing symptom coverage
Weekly Roadmap
1
W1-W2
Basic logging system for meds and symptoms is functional.
- •Build med/dose entry form with Strattera and stimulant presets
- •Create daily symptom rating scales for executive function and anhedonia
- •Set up local data storage
2
W3-W4
Combo comparison dashboard is complete.
- •Implement multi-med combo selection and tagging
- •Build simple visualization charts for symptom trends
- •Add exportable weekly summary reports
3
W5
Polish and internal validation with sample data.
- •UI refinements for mobile logging ease
- •Test with 3-5 simulated user regimens
- •Add basic data privacy settings
4
W6
Ready for beta launch and first users.
- •Implement Stripe subscription flow
- •Prepare onboarding templates for common ADHD combos
- •Draft community post for r/ADHD feedback
Launch Strategy
Launch in r/ADHD, r/Strattera, and r/adhdmedication communities with free basic tracker to convert active experimenters
RISKS & ASSUMPTIONS
Top Risks
Health data sensitivity
Users may hesitate to log sensitive medication data due to privacy concerns in a health app.
User logging consistency
Success depends on daily use; irregular logging reduces value of pattern analysis.
Medical disclaimer needs
Must clearly position as tracking tool only, not medical advice, to avoid liability.
Niche adoption speed
Limited to users actively experimenting with combos, which may be a smaller segment.
6
STAGE 06 · DECISION
Should you build it?
NEED A CLEARER CALL?
Run an Investment Memo to get a structured Go / No-Go verdict, competitor landscape, unit economics, and a 90-day validation roadmap for this opportunity.
Generate an investment memoWhat this score means
This idea scores in the upper-middle range of opportunities surfaced by MonetScope, with a validation sub-score of 7/10 against 3 independently sourced evidence signals. A "promising" rating usually indicates a real pain has been detected and discussed in the open, but the pipeline did not find enough signal to flag it as urgent or high-frequency. These opportunities can still produce excellent businesses — they often correspond to "boring" problems that established players have ignored — but the founder should expect a longer customer-development cycle to confirm willingness to pay.
Why this matters for SaaS founders
It sits at the intersection of "ai-powered", "data-management", "freelancers", which makes it relevant to a specific subset of founders rather than a generic horizontal opportunity. SaaS opportunities at this stage tend to win on the strength of their initial wedge — a single workflow that the target user runs every week, where the existing solution is either spreadsheets, a clunky incumbent feature, or a manual process they hate. The build cost is moderate; the distribution cost is everything. The MonetScope pipeline surfaces this category alongside other saas signals, which is why it appears here rather than in a generic "trending ideas" feed.
Scores are derived from real forum discussions across Reddit, Hacker News and X, weighted by evidence volume and signal quality. How scoring works
Frequently asked questions
Is "ComboCalm: ADHD Med Regimen Tracker for Balanced Symptom Coverage" a real validated startup idea or just an AI-generated suggestion?
MonetScope does not generate ideas from a language model's imagination. Every opportunity on this site is anchored to specific source posts and comments from real public discussions — typically on Reddit, Hacker News, or X — where actual users describe the pain in their own words. The AI's role is structuring, scoring, and grouping those signals into a navigable opportunity, not inventing the problem.
How recent is the underlying data for ai-powered?
MonetScope's spider pipeline runs continuously and surfaces opportunities as new evidence accumulates. The "Updated" date in the header reflects the most recent re-scoring of this specific opportunity. Most saas opportunities visible in the public catalog draw from discussions in the last 30-60 days; older signals are de-prioritized because user pain shifts faster than most founders assume.
What's the difference between "overall score" and "validation score"?
Overall score is a composite across six dimensions — pain, urgency, willingness to pay, market size, defensibility, and execution ease — designed to give a single number for triage. Validation score is narrower: it asks "how cleanly does the same signal repeat across independent sources?" An opportunity can score high on overall but lower on validation when one or two large discussions dominate the evidence; conversely, validation can be high on a smaller-overall idea where the signal is consistent but the addressable market is modest.